Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1 13Phase 3 6Phase 1/2 4Phase NA 3Phase 2/3 3Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Gynecologic 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × peginterferon alfa-2b × Clear all
NCT02089685 2022-09-13

MK-3475-029

Merck Sharp & Dohme LLC

Phase 1/2 Completed
295 enrolled 25 charts
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
12 enrolled 10 charts
Dermatologic

Melanoma

NCT00522249 2016-03-17

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

The Methodist Hospital Research Institute

Phase 1/2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00085384 2012-08-02

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡